48,706
edits
(→IHC) |
|||
(9 intermediate revisions by the same user not shown) | |||
Line 7: | Line 7: | ||
| Micro = inflammation ([[plasma cells]] - predominant, lymphocytes, eosinophils), [[spindle cells]] without atypia +/-fascicular architecture, +/-mitoses (none atypical), +/-[[necrosis]], +/-hemorrhage, +/-calcification | | Micro = inflammation ([[plasma cells]] - predominant, lymphocytes, eosinophils), [[spindle cells]] without atypia +/-fascicular architecture, +/-mitoses (none atypical), +/-[[necrosis]], +/-hemorrhage, +/-calcification | ||
| Subtypes = | | Subtypes = | ||
| LMDDx = [[calcifying fibrous pseudotumour]], [[inflammatory fibroid tumour]], [[nodular fasciitis]] | | LMDDx = [[calcifying fibrous pseudotumour]], [[inflammatory fibroid tumour]], [[nodular fasciitis]], [[gastrointestinal stromal tumour]], [[epithelioid inflammatory myofibroblastic sarcoma]] | ||
| Stains = | | Stains = | ||
| IHC = | | IHC = | ||
Line 37: | Line 37: | ||
*Mostly benign. | *Mostly benign. | ||
*Children & young adults. | *Children & young adults. | ||
May be treated with: | |||
*[[ALK inhibitors]].<ref name=pmid30790150>{{Cite journal | last1 = Honda | first1 = K. | last2 = Kadowaki | first2 = S. | last3 = Kato | first3 = K. | last4 = Hanai | first4 = N. | last5 = Hasegawa | first5 = Y. | last6 = Yatabe | first6 = Y. | last7 = Muro | first7 = K. | title = Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. | journal = Invest New Drugs | volume = | issue = | pages = | month = Feb | year = 2019 | doi = 10.1007/s10637-019-00742-2 | PMID = 30790150 }}</ref> | |||
*Drugs that act on ROS1 rearrangements, e.g. [[crizotinib]].<ref name=pmid30642440>{{Cite journal | last1 = Mai | first1 = S. | last2 = Xiong | first2 = G. | last3 = Diao | first3 = D. | last4 = Wang | first4 = W. | last5 = Zhou | first5 = Y. | last6 = Cai | first6 = R. | title = Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. | journal = Lung Cancer | volume = 128 | issue = | pages = 101-104 | month = Feb | year = 2019 | doi = 10.1016/j.lungcan.2018.12.016 | PMID = 30642440 }}</ref> | |||
==Gross== | ==Gross== | ||
Line 47: | Line 51: | ||
**[[Plasma cells]] - predominant - '''key feature'''.<ref name=pmid21297584>{{Cite journal | last1 = Saab | first1 = ST. | last2 = Hornick | first2 = JL. | last3 = Fletcher | first3 = CD. | last4 = Olson | first4 = SJ. | last5 = Coffin | first5 = CM. | title = IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link? | journal = Mod Pathol | volume = 24 | issue = 4 | pages = 606-12 | month = Apr | year = 2011 | doi = 10.1038/modpathol.2010.226 | PMID = 21297584 }}</ref> | **[[Plasma cells]] - predominant - '''key feature'''.<ref name=pmid21297584>{{Cite journal | last1 = Saab | first1 = ST. | last2 = Hornick | first2 = JL. | last3 = Fletcher | first3 = CD. | last4 = Olson | first4 = SJ. | last5 = Coffin | first5 = CM. | title = IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link? | journal = Mod Pathol | volume = 24 | issue = 4 | pages = 606-12 | month = Apr | year = 2011 | doi = 10.1038/modpathol.2010.226 | PMID = 21297584 }}</ref> | ||
**Lymphocytes. | **Lymphocytes. | ||
** | **[[Eosinophil]]s. | ||
*Spindle cells without atypia. | *Spindle cells without atypia. | ||
*+/-Fascicular architecture. | *+/-Fascicular architecture. | ||
Line 60: | Line 64: | ||
*[[Nodular fasciitis]]. | *[[Nodular fasciitis]]. | ||
*[[Gastrointestinal stromal tumour]].<ref name=pmid24938355>{{Cite journal | last1 = Kataoka | first1 = TR. | last2 = Yamashita | first2 = N. | last3 = Furuhata | first3 = A. | last4 = Hirata | first4 = M. | last5 = Ishida | first5 = T. | last6 = Nakamura | first6 = I. | last7 = Hirota | first7 = S. | last8 = Haga | first8 = H. | last9 = Katsuyama | first9 = E. | title = An inflammatory myofibroblastic tumor exhibiting immunoreactivity to KIT: a case report focusing on a diagnostic pitfall. | journal = World J Surg Oncol | volume = 12 | issue = | pages = 186 | month = | year = 2014 | doi = 10.1186/1477-7819-12-186 | PMID = 24938355 }}</ref> | *[[Gastrointestinal stromal tumour]].<ref name=pmid24938355>{{Cite journal | last1 = Kataoka | first1 = TR. | last2 = Yamashita | first2 = N. | last3 = Furuhata | first3 = A. | last4 = Hirata | first4 = M. | last5 = Ishida | first5 = T. | last6 = Nakamura | first6 = I. | last7 = Hirota | first7 = S. | last8 = Haga | first8 = H. | last9 = Katsuyama | first9 = E. | title = An inflammatory myofibroblastic tumor exhibiting immunoreactivity to KIT: a case report focusing on a diagnostic pitfall. | journal = World J Surg Oncol | volume = 12 | issue = | pages = 186 | month = | year = 2014 | doi = 10.1186/1477-7819-12-186 | PMID = 24938355 }}</ref> | ||
*[[IgG4-related systemic disease]].<ref name=pmid21297584/> | |||
*[[Epithelioid inflammatory myofibroblastic sarcoma]]. | |||
Notes: | Notes: | ||
Line 72: | Line 78: | ||
==IHC== | ==IHC== | ||
Features - dependent on site: | Features - dependent on site: | ||
*SMA +ve.<ref name=pmid20350216 >{{Cite journal | last1 = Shi | first1 = H. | last2 = Li | first2 = Y. | last3 = Wei | first3 = L. | last4 = Sun | first4 = L. | title = Primary colorectal inflammatory myofibroblastic tumour: a clinicopathological and immunohistochemical study of seven cases. | journal = Pathology | volume = 42 | issue = 3 | pages = 235-41 | month = Apr | year = 2010 | doi = 10.3109/00313021003631312 | PMID = 20350216 }} | *SMA +ve.<ref name=pmid20350216>{{Cite journal | last1 = Shi | first1 = H. | last2 = Li | first2 = Y. | last3 = Wei | first3 = L. | last4 = Sun | first4 = L. | title = Primary colorectal inflammatory myofibroblastic tumour: a clinicopathological and immunohistochemical study of seven cases. | journal = Pathology | volume = 42 | issue = 3 | pages = 235-41 | month = Apr | year = 2010 | doi = 10.3109/00313021003631312 | PMID = 20350216 }}</ref> | ||
</ref> | |||
*Vimentin +ve. | *Vimentin +ve. | ||
*ALK-1 +ve.<ref name=pmid15577680>{{Cite journal | last1 = Tsuzuki | first1 = T. | last2 = Magi-Galluzzi | first2 = C. | last3 = Epstein | first3 = JI. | title = ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. | journal = Am J Surg Pathol | volume = 28 | issue = 12 | pages = 1609-14 | month = Dec | year = 2004 | doi = | PMID = 15577680 }}</ref> | *ALK-1 +ve.<ref name=pmid15577680>{{Cite journal | last1 = Tsuzuki | first1 = T. | last2 = Magi-Galluzzi | first2 = C. | last3 = Epstein | first3 = JI. | title = ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. | journal = Am J Surg Pathol | volume = 28 | issue = 12 | pages = 1609-14 | month = Dec | year = 2004 | doi = | PMID = 15577680 }}</ref> | ||
*CD117 -ve. | *CD117 -ve. | ||
**Case report of CD117 +ve.<ref name=pmid24938355/> | **Case report of CD117 +ve.<ref name=pmid24938355/> | ||
*CD30 -ve. | |||
Variable staining with: | Variable staining with: | ||
Line 87: | Line 93: | ||
==Molecular== | ==Molecular== | ||
*ALK rearrangements.<ref name=pmid21297584/> | *ALK rearrangements.<ref name=pmid21297584/> | ||
*ROS1 rearrangements.<ref name=pmid30642440>{{Cite journal | last1 = Mai | first1 = S. | last2 = Xiong | first2 = G. | last3 = Diao | first3 = D. | last4 = Wang | first4 = W. | last5 = Zhou | first5 = Y. | last6 = Cai | first6 = R. | title = Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. | journal = Lung Cancer | volume = 128 | issue = | pages = 101-104 | month = Feb | year = 2019 | doi = 10.1016/j.lungcan.2018.12.016 | PMID = 30642440 }}</ref> | |||
==See also== | ==See also== |
edits